Presentation of new phenytoin cream data at NeuPSIG 2017

Presentation of new phenytoin cream data at NeuPSIG 2017

Topical Innovations had the opportunity to share newest clinical findings on the role of topical phenytoin in neuropathic pain, at a workshop at the NeuPSIG 2017, June 15th, at Gothenburg, Sweden. The session was related to the sodium channel as a new target for neuropathic pain: ‘Testing sodium channel function in neuropathic pain’.

From January 2017 until June 2017 4.5 kilo of phenytoin 5% cream (corresponding to 150 tubes of 30 grams) and 26 kilo of phenytoin 10% cream (corresponding to 866 tubes of 30 gram) are compounded by the Dutch pharmacists related to the Institute of Neuropathic Pain, and sent to patients for the treatment of neuropathic pain (see graph).
Furthermore, more than 200 patients have used these phenytoin creams to date (see table).
Many of them have re-ordered the analgesic cream, indicating their satisfaction. Serious adverse events have not been reported.

Furthermore, Topical Innovations has thoroughly documented data on 40 patients using the analgesic cream with positive results.

 

Topical cream Prescriptions Patients
Phenytoin 10% 247 147
Phenytoin 5% 76 51
Phenytoin 5%/Baclofen 5% 18 9

Growing popularity of topiceuticals

Growing popularity of topiceuticals

In 2017 topiceuticals, topical formulations, are increasingly referred to in pain medicine. In a recent state of the art review by Peter Paisley and Michael Serpell the following was highlighted: ‘Topiceuticals should be considered in a diagnosis of LNP, particularly in the frail and elderly population.’ and ‘The role of other topiceuticals has yet to be fully evaluated but small numbered trials have shown promise.’

The authors stressed the important fact that in around half of cancer patients with neuropathic pain consistent and circumscribed area of maximum pain have been described, as ‘localized neuropathic pain” (LNP). LNP forms the basis for using topiceuticals in cancer-related pain. The authors stipulate the use of topiceuticals in localized neuropathic pain associated with malignancy as a valuable option with many advantages over systemic treatments.

Reference
Paisley P, Serpell M. The role of topiceuticals in cancer pain. Curr Opin Support Palliat Care. 2017 Jun;11(2):93-98.

Neuropathic pain treatment update

Neuropathic pain treatment update

At the at plenary session of the NeuPSIG 2017 at Gothenburg, Sweden (June 2017) professor Bouhassira presented a Neuropathic Pain Treatment Update. He stipulated that not much new leads are currently in clinical development. He highlighted the importance to look for repositioning of old drugs in neuropathic pain, as well as the role of sodium channel blockers. Read more here.

Neuropathic itch

Neuropathic itch

At the plenary session at the NeuPSIG 2017 at Gothenburg, Sweden a topic discussed was Neuropathic Itch. A state of the art lecture was given by professor Sarah Ross, USA, who outlined the pathophysiology of neuropathic itch. In the linked report, the use of topical phenytoin for neuropathic itch was highlighted. Read more here.